<DOC>
	<DOCNO>NCT00001573</DOCNO>
	<brief_summary>A dose escalation scale consist 5 dosage level use determine maximum tolerate dose ( MTD ) SU101 . A minimum 3 maximum 6 patient enrol dose level . MTD define dose level immediately 2 patient exhibit dose limit toxicity . Each treatment cycle 21 day . Patients receive 96 hour continuous IV infusion SU101 day 1-4 .</brief_summary>
	<brief_title>A Phase I Study SU101 Pediatric Patients With Refractory Malignancy</brief_title>
	<detailed_description>SU101 member novel class antineoplastic agent , platelet-derived growth factor ( PDGF ) receptor inhibitor . Preclinical data suggest SU101 might effective agent neuroglial tumor well variety sarcoma . A pediatric phase I trial SU101 child malignancy conduct find maximum tolerate dose SU101 define toxicity profile agent . In addition , define pharmacokinetics SU101 active metabolite SU0020 pediatric patient gather preliminary information regard response .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primary CNS malignancy , neuroblastoma sarcoma refractory standard therapy standard therapy exist disease cure surgery . PRIOR/CONCURRENT THERAPY : Recovered toxic affect prior therapy . No investigational agent within past 2 week . BIOLOGY THERAPY : Not specify . CHEMOTHERAPY : No myelosuppressive therapy within past 3 week . No nitrosourea within past 6 week . ENDOCRINE THERAPY : If receive dexamethasone dose must stable least 2 week . RADIOTHERAPY : Not specify . SURGERY : Not specify . PATIENT CHARACTERISTICS : Age : 3 21 . Performance status : ECOG 02 . Life expectancy : At least 8 week . HEMATOPOIETIC : AGC great 1500/mm ( 3 ) . Hemoglobin great equal 8.0 g/dL percent . Platelet count great 100,000/mm ( 3 ) . For patient bone marrow involvement history bone marrow transplantation craniospinal radiotherapy : AGC great 750/mm ( 3 ) , Hemoglobin great 6.0 g/dL , Platelet count great 50,000/mm ( 3 ) . HEPATIC : SGOT , SGPT alkaline phosphatase less 3 time upper limit normal . Bilirubin le equal 1.5 time upper limit normal . RENAL : Ages 35 Creatinine great 0.8 mg/dL . Ages 510 Creatinine great 1.0 mg/dL . Ages 1015 Creatinine great 1.2 mg/dL . Ages 1621 Creatinine great 1.5 mg/dL . OTHER : All patient legal guardian ( patient 18 year old ) must sign document inform consent indicate understanding investigational nature risk study . For patient brain tumor 18 year age , DPA sign . Not pregnant nursing . Not allergic etoposide . No acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation/study drug administration may interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>Glioma</keyword>
	<keyword>PDGF</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Toxicity</keyword>
</DOC>